<DOC>
	<DOCNO>NCT01044537</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability , pharmacokinetics , pharmacodynamics PF-04937319 follow single escalate oral dos adult subject Type 2 Diabetes Mellitus ( T2DM ) .</brief_summary>
	<brief_title>A Trial To Assess The Safety , Tolerability , Pharmacokinetics , And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The purpose phase 1 study characterize safety , tolerability , pharmacokinetics , pharmacodynamics PF04937319 follow single escalate oral dos adult subject T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes mellitus take stable dos metformin . Subjects treat sulfonylurea ( SU ) dipeptidyl peptidaseIV inhibitor ( DPPIVi ) combination metformin may eligible washed SU DPPIVi metformin minimum 4 week dose . Male and/or female subject ( female woman non childbearing potential ) age 18 65 year , inclusive , body mass index ( BMI ) 18.5 45.0 kg/m2 Cpeptide &gt; 0.8 ng/mL . Screening Day 2 troponin I concentration &lt; /=0.05 ng/mL measure Bayer Centaur Ultra assay . HbA1c &gt; /=7 % &lt; /=11 % . If patient require washed SU DPPIVi , HbA1c limit &gt; /=7 % &lt; /=9.5 % . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Evidence history diabetic complication significant end organ damage , eg , proliferative retinopathy and/or macular edema , creatinine clearance &lt; /=60 mL/min base CockcroftGault equation , diabetic neuropathy complicate neuropathic ulcer . History stroke , transient ischemic attack , myocardial infarction within past 6 month . Additionally , history coronary artery bypass graft stent implantation , clinically significant peripheral vascular disease , congestive heart failure ( NYHA Classes IIIV ) . Furthermore , current history angina/unstable angina . Also , 12 lead electrocardiogram ( ECG ) demonstrate QTc &gt; 450 msec screening , ECG finding suggestive asymptomatic myocardial ischemia , supine blood pressure &gt; /=160 mm Hg ( systolic ) &lt; /=100 mm Hg ( diastolic ) . One self report episode hypoglycemia within last 3 month , two self report episode hypoglycemia within last 6 month . Screening Day 2 fasting ( &gt; /=8 hour ) blood glucose , &lt; /=70 &gt; /=270 mg/dL , confirm single repeat deem necessary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>phase 1</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>T2DM</keyword>
</DOC>